Patient Guide: Evaluating the Addition of Elacestrant (Oral SERD) to Olaparib (PARP-inhibitor) in Patients With Advanced/Metastatic HR+/HER2- Breast Cancer

We'll Help You Connect with This Trial

Quri.ai is a free clinical trial matching service. We help patients like you connect directly with research sites conducting this study.

  • Get matched to the right study location for you
  • Connect directly with study coordinators at 36 participating sites
  • Understand eligibility with our simplified screening tool
  • Free service - we're here to help you access clinical research
Trial ID: NCTNCT06201234
Status: 🟢 Enrolling Now
Condition: Hormone Receptor Positive HER-2 Negative Breast Cancer, Advanced or Metastatic Breast Cancer, BRCA1 Mutation, BRCA2 Mutation
Phase: PHASE2

Find a Study Location Near You

This study is available at 36 research sites. We'll help you connect with the location that's right for you.

Participating sites include:
  • Stuttgart, Baden-Wurttemberg
  • Tübingen, Baden-Wurttemberg
  • Winnenden, Baden-Wurttemberg
  • • And 33 more locations - let us help you find the closest one

Loading interactive enrollment tools...

The full interactive experience will load momentarily